Lifeward Ltd. Reports $11.4 Million Net Loss and Revenue Decline for First Half of 2025

Lifeward Ltd. reported a net loss of $11.4 million for the six months ending June 30, 2025, compared to a loss of $10.6 million during the same period in 2024. The company's revenues decreased to $10.8 million from $12.0 million year-over-year, reflecting a decline in product sales and service revenues. For the second quarter of 2025, Lifeward generated $5.7 million in revenue, down from $6.7 million in the prior year. The gross profit for the first half of 2025 was $4.6 million, an increase from $4.2 million in the same period last year, primarily due to a reduction in cost of revenues.

The company experienced significant changes in its financial position, with total assets decreasing to $26.8 million as of June 30, 2025, from $30.5 million at the end of 2024. Cash and cash equivalents also fell to $5.1 million from $6.7 million. Lifeward's accumulated deficit increased to $276.2 million, up from $264.8 million at the end of 2024. The decline in cash reserves and the ongoing operating losses raise substantial doubt about the company's ability to continue as a going concern for the next twelve months, as management anticipates needing additional funding to support operations.

Strategically, Lifeward has made notable developments, including the acquisition of AlterG, Inc. in August 2023, which has since been integrated into Lifeward's operations. The company has also rebranded from ReWalk Robotics to Lifeward, reflecting a broader focus on rehabilitation solutions. Lifeward's product offerings now include the ReWalk and ReStore exoskeletons, as well as the AlterG Anti-Gravity systems, which are marketed directly to rehabilitation facilities and through distributors in various countries, including the U.S., Germany, Canada, and Australia.

Operationally, Lifeward reported a decrease in customer engagement, with product revenues falling to $8.3 million for the first half of 2025 from $8.9 million in 2024. The company has also seen a decline in its employee headcount, which may impact its operational capacity. Lifeward's management has indicated that the company is focusing on cost reduction initiatives and operational efficiencies to navigate the current market conditions. The company is also exploring opportunities for geographic expansion and product adoption, particularly in light of the recent establishment of a Medicare reimbursement pathway for its ReWalk products.

Looking ahead, Lifeward's management has expressed cautious optimism about future growth, contingent on successfully raising additional capital and maintaining compliance with Nasdaq requirements. The company aims to leverage its expanded product portfolio and the integration of AlterG to enhance its market position. However, the ongoing challenges related to cash flow and operational losses underscore the need for strategic financial planning and execution to ensure sustainability and growth in the coming quarters.